

## Supplementary Table S1

**TESTED PERSON CARD**
**First Name and Last Name:** .....

**Date and place of birth:**.....

**Address:** .....

**Contact phone number, e-mail:** .....

**Gender:**            **M**            **F**

Test date: .....

Age (in years): .....

Smoking: **YES / NO**

Have you ever been diagnosed with the presence of SARS-CoV-2 RNA? If so, at what time before the test?  
**YES / NO** .....

Have you had contact with a person who was diagnosed with SARS-CoV-2 RNA (if so, when)? **YES / NO**  
.....

Have you been in quarantine for COVID-19 (if so, when)? **YES / NO** .....

Have you had a respiratory infection in the last six months? **YES / NO**

If YES:

- when? ..... and how long did it take? .....
- what were the symptoms (please underline)?: cough / runny nose / fever / low-grade fever / muscle or joint pain / sore throat / diarrhea / conjunctivitis / headache / loss of taste or smell / skin rash / discoloration of fingers and toes / difficulty breathing or shortness of breath / chest pain or tightness / loss of speech or motor skills / disorientation

Have you traveled outside of your place of residence in the last six months (if so, where - region / country)?  
**YES / NO** .....

Do you have a pet? **YES / NO** (what?) .....

Past infectious diseases in the last 5 years **YES / NO** (what?) .....  
.....

Chronic diseases **YES / NO** (what?) .....

Autoimmune diseases **YES / NO** (what?) .....

Allergies **YES / NO** .....

Vitamin D supplementation **YES / NO** .....

Supplementary Table S2

| Patient ID |     | Date of positive SARS-CoV-2 result | July        |      | August      |           | September  |            | October     |             | November   |           | December/*January |             |
|------------|-----|------------------------------------|-------------|------|-------------|-----------|------------|------------|-------------|-------------|------------|-----------|-------------------|-------------|
|            |     |                                    | IgA         | IgG  | IgA         | IgG       | IgA        | IgG        | IgA         | IgG         | IgA        | IgG       | IgA               | IgG         |
| 1.         | 117 | 2020-06-11                         | n-ex        | n-ex | + (2.300)   | + (2.630) | + (4.604)  | + (2.054)  | + (2.531)   | + (1.691)   | + (3.218)  | + (1.832) | + (3.038)         | + (1.576)   |
| 2.         | 118 | 2020-06-11                         | n-ex        | n-ex | + (5.664)   | + (4.172) | + (> 9.99) | + ( 4.558) | + (7.787)   | + (5.397)   | + (> 9.99) | + (6.878) | + (> 9.9)         | + (8.895)   |
| 3.         | 109 | 2020-09-15                         | -           | -    | -           | -         | -          | -          | -           | -           | + (1.569)  | + (1.986) | + (1.117)         | + (3.182)   |
| 4.         | 32  | 2020-10-03                         | +/- (1.036) | -    | +/- (0.961) | -         | + (1.428)  | -          | n-ex        | n-ex        | + (3.055)  | + (1.584) | + (1.108)         | + (1.268)   |
| 5.         | 35  | 2020-10-05                         | -           | -    | -           | -         | -          | -          | + (1.363)   | +/- (0.908) | + (2.389)  | + (2.187) | + (1.856)         | + (2.279)   |
| 6.         | 122 | 2021-10-10                         | n-ex        | n-ex | n-ex        | n-ex      | n-ex       | n-ex       | -           | -           | + (5.415)  | + (6.615) | + (1/759)         | + (7.135)   |
| 7.         | 95  | 2020-10-26                         | -           | -    | -           | -         | -          | -          | -           | -           | + (1.574)  | - (0.611) | + (1.403)         | +/- (1.011) |
| 8.         | 70  | 2020-10-29                         | -           | -    | -           | -         | -          | -          | -           | -           | n-ex       | n-ex      | + (7.875)         | + (4.234)   |
| 9.         | 116 | 2020-10-30                         | -           | -    | -           | -         | -          | -          | -           | -           | n-ex       | n-ex      | +/- (0.943)       | +/- (0.958) |
| 10.        | 42  | 2020-11-02                         | -           | -    | -           | -         | -          | -          | +/- (0.839) | -           | n-ex       | n-ex      | + (7.183)         | + (5.261)   |
| 11.        | 54  | 2020-11-04                         | -           | -    | n-ex        | n-ex      | n-ex       | n-ex       | n-ex        | n-ex        | n-ex       | n-ex      | + (5.420)         | + (5.824)   |
| 12.        | 112 | 2020-11-05                         | n-ex        | n-ex | -           | -         | -          | -          | -           | -           | -          | -         | >9.999*           | 9.381*      |
| 13.        | 56  | 2020-11-14                         | -           | -    | -           | -         | -          | -          | -           | -           | -          | -         | 7.692*            | 4.976*      |
| 14.        | 9   | 2020-11-15                         | -           | -    | -           | -         | -          | -          | -           | -           | -          | -         | 0.632*            | 3.330*      |
| 15.        | 28  | 2020-11-18                         | -           | -    | -           | -         | -          | -          | -           | -           | -          | -         | - (0.667)         | +/- (0.926) |
| 16.        | 76  | 2020-11-22                         | -           | -    | -           | -         | -          | -          | -           | -           | -          | -         | + (3.669)         | + (5.160)   |
| 17.        | 53  | 2020-11-23                         | -           | -    | -           | -         | -          | -          | -           | -           | n-ex       | n-ex      | + (6.071)         | + (2.482)   |
| 18.        | 89  | 2020-11-23                         | -           | -    | -           | -         | -          | -          | -           | -           | -          | -         | + (2.45)          | + (2.558)   |
| 19.        | 83  | 2020-11-27                         | -           | -    | -           | -         | -          | -          | -           | -           | n-ex       | n-ex      | + (5.748)         | +/- (0.921) |
| 20.        | 86  | 2020-11-27                         | -           | -    | -           | -         | -          | -          | -           | -           | -          | -         | + (2.632)         | + (1.973)   |
| 21.        | 50  | 2020-11-30                         | -           | -    | -           | -         | -          | -          | -           | -           | -          | -         | + (1.456)         | + (4.876)   |
| 22.        | 85  | 2020-11-30                         | -           | -    | -           | -         | -          | -          | -           | -           | -          | -         | + (7.891)         | + (3.445)   |
| 23.        | 87  | 2020-11-30                         | -           | -    | -           | -         | -          | -          | -           | -           | -          | -         | + (2.530)         | - (0.344)   |
| 24.        | 13  | 2020-11-30                         | -           | -    | -           | -         | -          | -          | -           | -           | -          | -         | + (8.023)         | + (2.013)   |
| 25.        | 73  | 2020-12-01                         | -           | -    | -           | -         | -          | -          | -           | -           | -          | -         | - (0.671)         | + (3.944)   |
| 26.        | 82  | 2020-12-03                         | -           | -    | -           | -         | -          | -          | -           | -           | -          | -         | 2.364*            | 2.741*      |
| 27.        | 34  | 2020-12-07                         | -           | -    | -           | -         | n-ex       | n-ex       | -           | -           | -          | -         | 6.653*            | >9.999*     |
| 28.        | 41  | 2020-12-07                         | -           | -    | -           | -         | -          | -          | +/- (0.821) | -           | n-ex       | n-ex      | + (4.425)         | + (1.705)   |
| 29.        | 71  | 2020-12-31                         | -           | -    | -           | -         | -          | -          | -           | -           | -          | -         | - / n-ex          | - / n-ex    |

Abbreviation: n-ex – non examined (absence of participants - related with disease or quarantine/isolation); \* specimen collected in January 2021; + positive result; - negative result; +/- borderline result; () ratio of antibodies in semi-quantitative test (Euroimmun)